Patients eligible for modulator drugs: Data from cystic fibrosis registry of Turkey

Date
2020
Author
Harmanci, Koray
Cokugras, Haluk
Kilinc, Ayse Ayzit
Al Shadfan, Lina Muhammed
Yazan, Hakan
Altintas, Derya Ufuk
Karagoz, Dilek
Demir, Esen
Ozturk, Gokcen Kartal
Bingol, Aysen
Basaran, Abdurrahman Erdem
Sapan, Nihat
Cekic, Sukru
Celebioglu, Ebru
Aslan, Ayse Tana
Gursoy, Tugba Ramasli
Tugcu, Gokcen
Ozdemir, Ali
Ercan, Omur
Yildirim, Gonca Kilic
Kose, Mehmet
Hangul, Melih
Suleyman, Ayse
Yuksel, Hasan
Yilmaz, Ozge
Ozcan, Gizem
Topal, Erdem
Can, Demet
Ekren, Pervin Korkmaz
Caltepe, Gonul
Kilic, Mehmet
Ozdogan, Sebnem
Dogru, Deniz
Cobanoglu, Nazan
Ozcelik, Ugur
ÇAKIR, Erkan
Eyuboglu, Tugba Sismanlar
Pekcan, Sevgi
Cinel, Guzin
Yalcin, Ebru
Kiper, Nural
EMİRALİOĞLU, NAGEHAN
Sen, Velat
TAMAY, Zeynep Ülker
Sen, Hadice Selimoglu
Metadata
Show full item record
Abstract
Background A better understanding of cystic fibrosis transmembrane conductance regulator biology has led to the development of modulator drugs such as ivacaftor, lumacaftor-ivacaftor, tezacaftor-ivacaftor, and elexacaftor-tezacaftor-ivacaftor. This cross-sectional study evaluated cystic fibrosis (CF) patients eligible for modulator drugs.
URI
http://hdl.handle.net/20.500.12627/3680
https://doi.org/10.1002/ppul.24854
Collections